If you have followed Immune Pharmaceuticals as I have, you are very pleased (as I am) to see it move to NASDAQ Capital Markets. The liquidity for this stock will grow even more rapidly. We see some positive news just out of another pharmaceutical favorite of ours, so be watching for that one as we profile in detail Skinvisible Inc. (SKVI) in detail over the next few months.
For now, here is the news from Immune Pharmaceuticals:
Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: “IMNP”), a biotechnology company, today announced that it has received confirmation that its application to list its common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. IMMUNE’s common stock is expected to begin trading on the NASDAQ Capital Market at the opening of trading on August 21, 2014 under the symbol IMNP.
“We believe that trading on NASDAQ will enhance our visibility, increase our liquidity and provide access to a broader institutional investor base,” said Dr. Daniel Teper, Chief Executive Officer of IMMUNE. “Uplisting to NASDAQ represents a significant milestone for IMMUNE as it gives us the opportunity to accelerate the development of Bertilimumab and other important drugs in our portfolio.”
IMMUNE’s common stock will continue to trade on the OTCQX under its existing ticker symbol “IMNP” until the market closes on August 20, 2014. IMMUNE also continues to be traded on NASDAQ OMX First North Premier in Stockholm.